REFERENCES
- Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995; 50: 364—95
- Carr BR. Re-evaluation of oral contraceptive classifications, bit J Fértil 1997; 42(Suppl 1): 133–44
- Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612-17, 672–7
- Fotherby K, Caldwell A. New progestogens in oral contraception. Contraception 1994; 49: 1–32
- Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995; 29: 736–42
- Kuhl H. Comparative pharmacology of the newer progestogens. Drugs 1996; 51: 188–215
- SperofFL, DeCherney A, the Advisory Board for New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993; 81: 1034–47
- Endrikat J, Jaques MA, Mayerhofer M, et al. A twelvemonth comparative clinical investigation of two low-dose oral contraceptives containing 20 µg ethinyl estradiol/75 µg gestodene and 20 µg ethinyl estradiol/ 150 µg desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52: 229–35
- Düsterberg B, Ellman H, Müller U, et al. A three-yearclinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996; 10: 33–9
- Kirkman RJ, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception 1994; 49: 33–46
- Tietze C, Lewit S. Statistical evaluation of contraceptive methods. Clin Obstet Gynecol 1974; 17: 121–38
- Fitzgerald C, Feichtinger W, SponaJ. A comparison of the effects of two monophasic low-dose contraceptives on the inhibition of ovulation. Adv Contracept 1994; 10: 5–18
- Eyong E, Elstein M. Clinical update on a new progestogen - gestodene. BrJFam Piami 1989; 15: 18–22
- Gestodene Study Group 324. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 µg/ ethinylestradiol 15 µg and a 21-day regimen of desogestrel 150 µg/ethinylestradiol 20 µg. Eur J Contracept Reprod Health Care 1999; 4 (Suppl 2): 17–25
- Guillebaud J. Contraception Today. A Pocketbook for General Practitioners, 3rd edn. London: Martin Dunitz, 1997
- Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129–40
- Schwartz SM, Siscovick DS, Longstreth WT Jr, et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997; 127: 596–603
- Lidegaard L, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996; 53: 135–9
- Sullivan H, Furniss H, SponaJ, Elstein M. Effects of 21-day and 24-day oral contraceptive regimens containing gestodene (60 µg) and ethinyl estradiol (15 µg) on ovarian activity. Fértil Steril 1999; 72: 115–20